SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

"What's Updog?" is a Community Led token.

UpDog

UpDog is trending, and the community is actively engaging with the classic "What's UpDog?" joke, driving social volume. Some users are pointing out the project has been live on Solana for over a year and has a locked and burned LP. Others suggest the recent increase in social volume is due to only one or two accounts.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: Cybersecurity, Internet of Things (IoT), and Licensing and Other. The Cybersecurity segment includes the brand Cylance, BlackBerry Spark, AtHoc, and SecuSUITE. The IoT segment focuses on software licenses, support, maintenance, and professional services. The Licensing and Other segment involves the intellectual property licensing arrangements and settlement awards. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is trending as investors anticipate upcoming earnings, with community members highlighting the potential impact of QNX technology and key partnerships with companies like AMD and Nvidia. Bullish sentiment is fueled by expectations of strong financial performance and the possibility of future share buybacks. Some investors suggest BlackBerry is undervalued, drawing comparisons to AMD's earlier growth trajectory.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics is trending due to positive Phase 2 trial results for their hidradenitis suppurativa treatment, sonelokimab, which has sparked considerable excitement and discussion within the biotech community. Community members are actively debating the potential for a buyout, comparing the company's prospects to competitors, and analyzing the implications of a possible public offering. The stock's movement is also influenced by discussions about short squeezes and technical indicators.

Blockchain-on-Blockchain (BOB) is a new blockchain built on top of another blockchain called ICP. It's like a special layer on an existing system. BOB creates a secure digital record book that uses ICP's network for safety. BOB uses a system called 'proof-of-on-chain-work': You deploy your own smart contract (canister) at bob.fun. This program solves math problems (hashes). Main computers (mother nodes) give out these problems. Miners solve the problems and tell the mother node. If correct, the mother node adds a new block to the blockchain. The winning miner gets BOB tokens as a reward.

BOB.X is trending as users discuss its potential as the next BTC.X, highlighting its capped supply and upcoming halving event. Community members are also excited about its multi-chain availability and integration within the ICP.X ecosystem.

ResMed, Inc. engages in providing digital health and cloud-connected medical devices. Its digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, chronic obstructive pulmonary disease, or COPD, and other chronic diseases. The firm operates through the Sleep and Respiratory Care and Software as a Service segments. The Sleep and Respiratory Care segment engages in the sleep and respiratory disorders sector of the medical device industry. The Software as a Service segment provides business management software as a service to out-of-hospital health providers. The company was founded by Peter C. Farrell in June 1989 and is headquartered in San Diego, CA.

Resmed Inc.

Resmed ($RMD) is trending as the community speculates about potential partnerships or a buyout of Incannex ($IXHL), fueled by the presence of a ResMed representative on Incannex's advisory board and upcoming phase 2 results for Incannex's sleep apnea pill.  The community believes positive trial outcomes could make Incannex a compelling acquisition target in the competitive sleep apnea treatment market, while others believe a strategic alliance is more likely. Some traders are closely watching for a formal announcement during ResMed's earnings call.

Meet Pandu — your AI friend who’s always by your side. Talk with him in real time through text or voice, share your thoughts, ask questions, or just enjoy a casual conversation. Whether you’re looking for advice, company, or simply someone to listen, Pandu is here as a true companion you can connect with anytime.  Pandu unites real-time conversation, creative generation, and future-ready AI systems — all powered by next-gen technology.

Pandu Pandas

Pandu Pandas is trending as the community discusses its recent listing on MEXC and potential for significant growth. Comparisons to other tokens like PENGU are circulating, with many highlighting its strong fundamentals and NFT presence. Holders are expressing bullish sentiment, anticipating a potential breakout and encouraging others to research the token.

Ouster, Inc. engages in the provision of high resolution digital lidar sensors that offer advanced 3D vision to machinery, vehicles, robots, and fixed infrastructure assets. The company was founded by Angus Pacala and Mark Frichtl on June 30, 2015 and is headquartered in San Francisco, CA.

Ouster Inc - Ordinary Shares - Class A

OUST is trending as investors react to news of increasing adoption of its lidar technology in diverse sectors like traffic management (Utah deployment) and security, and a potential breakout into the $100B security market. Bullish sentiment is fueled by consecutive quarters of revenue growth, zero debt, and growing cash reserves, with some community members anticipating a rise to $50. Discussions also highlight OUST as a key player in the physical AI space and a potential acquisition target.

Invesco DB US Dollar Index Trust - Invesco DB US Dollar Index Bullish Fund

Invesco DB US Dollar Index Bullish Fund

The U.S. Dollar Index ($UUP) is trending as traders weigh the potential impact of a strong dollar against expectations for future Federal Reserve policy. Community members are analyzing technical indicators and potential breakout levels, while also considering the impact of tariffs and trade deals. Discussions revolve around the dollar's relationship with other asset classes like gold and equities.

Marathon Petroleum Corp. engages in the refining, marketing, and transportation of petroleum products. It operates through the Refining and Marketing, and Midstream segments. The Refining and Marketing segment includes refining crude oil and other feedstocks, purchasing ethanol, and refined products for resale and distribution of refined products. The Midstream segment refers to transportation, storing, distribution, and marketing of crude oil and refined products. The company was founded in 1887 and is headquartered in Findlay, OH.

Marathon Petroleum Corp

Marathon Petroleum is trending amid unusual options activity and high trading volume, suggesting bullish sentiment among some investors. Community members are actively discussing potential ROI from call options, while recent reports highlight the company's solid financial position and potential as a 'refiner cash cow' given disruptions in global oil markets.

WeRide, Inc. is a holding company, which engages in the sale of autonomous driving vehicles, primarily including robobuses, robotaxis, robosweepers, and related sensor suites. The company was founded by Tony Xu Han and Yan Li on March 13, 2017 and is headquartered in Guangzhou, China.

WeRide Inc. - ADR

WeRide ($WRD) is trending due to discussions around its partnerships and deployments in the Middle East and Southeast Asia, including Singapore and Abu Dhabi. The community is debating whether WeRide is undervalued compared to competitors like Pony.ai, despite its revenue growth and expansion. Recent news of UBS initiating coverage with a buy rating and the upcoming Grab earnings call are also fueling interest.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

GEHC Inks License Agreement With Lantheus for Prostate Imaging Agent

GE HealthCare strengthens its radiopharmaceutical portfolio by licensing Lantheus' PSMA PET imaging agent, PYLARIFY, for commercialization in Japan.

Masimo Completes Divestment of Consumer Audio Business to HARMAN

MASI completes sale of Sound United to HARMAN, sharpening focus on core healthcare, boosting margins, and funding buybacks.

Here's Why You Should Add Inogen Stock to Your Portfolio Now

Expanding product portfolio and high prospects for POC raise optimism for INGN stock.

Reasons to Add West Pharmaceutical Stock to Your Portfolio Now

WST rides on GLP-1 demand and Annex 1 expansion, but margins face pressure from pricing and tariff headwinds.

Wall Street Analysts See a 35.64% Upside in Inogen (INGN): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 35.6% in Inogen (INGN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

3 Top Medical Instruments Stocks Defying Tariff Pressure With GenAI

Teleflex, Integer Holdings and Inogen are defying tariff and supply chain headwinds with genAI-driven momentum within the Medical Instruments industry.

Wall Street Analysts Think Inogen (INGN) Could Surge 49.25%: Read This Before Placing a Bet

The mean of analysts' price targets for Inogen (INGN) points to a 49.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Inogen Stock Gains Following Q2 Earnings Beat, Revenues Up Y/Y

INGN stock rises as Q2 loss narrows and revenue climbs 4% year over year, driven by strong B2B demand despite DTC and rental declines.

Inogen (INGN) Reports Q2 Loss, Beats Revenue Estimates

Inogen (INGN) delivered earnings and revenue surprises of +31.82% and +1.76%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Masimo (MASI) Beats Q2 Earnings and Revenue Estimates

Masimo (MASI) delivered earnings and revenue surprises of +8.13% and +0.59%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Inogen, Inc. is a medical technology company, which engages in the development, manufacture, and marketing of portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. Its products include Inogen One G4 system, Inogen One G3 system, Inogen One G5 system, Inogen TAV, and Inogen at Home. The company was founded by Alison Perry, Alison K. Bauerlein, Brenton Taylor, and Byron Myers on November 27, 2001 and is headquartered in Goleta, CA.

Inogen Inc

Will the U.S. government shut down in 2025? 
 
*Powered by Polymarket

Current Price	$8.22
Prev Close	$8.46
Open	$8.46
Dividend Yield	0.00%
50-Day Moving Average	$7.55
Beta	1.36
Avg. Volume	265,863.57
PE Ratio	-7.76

52-Week High	$12.91
52-Week Low	$5.70
Market Capitalization	$222.27M
EPS (Annual)	-$1.52
Price to Book	1.11
Revenue Per Employee	$438,257.18
Enterprise Value/EBITDA	N/A

INGN
Inogen Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest INGN News

INGN Inogen Inc